LIFE - aTyr Pharma, Inc.
| Previous Close | 4.2900 |
| Open | 4.3000 |
| Bid | 4.3300 x 1000 |
| Ask | 4.3500 x 4000 |
| Day's Range | 4.2210 - 4.4050 |
| 52 Week Range | 2.7600 - 10.0800 |
| Volume | 13,078 |
| Avg. Volume | 29,385 |
| Market Cap | 16M |
| Beta (3Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.1990 |
| Earnings Date | Nov 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Thomson Reuters StreetEvents
Edited Transcript of LIFE earnings conference call or presentation 14-Nov-19 10:00pm GMT
Q3 2019 aTyr Pharma Inc Earnings Call
- GlobeNewswire
aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update
Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast.
- GlobeNewswire
aTyr Pharma to Present at the Stifel Healthcare Conference 2019
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr, will be presenting at the Stifel Healthcare Conference 2019, which is being held November 19-20 in New York.
- GlobeNewswire
aTyr Pharma to Announce Third Quarter Results on November 14th
SAN DIEGO, Nov. 07, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire
aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company has entered into a research collaboration with Boston Children’s Hospital. Dr. Diane Bielenberg, Assistant Professor in the Department of Surgery at Harvard Medical School and a Research Associate in the Vascular Biology Program at Boston Children’s, will serve as the principal investigator for the collaboration. Dr. Bielenberg is an expert in the field of neuropilin-2 (NRP2) biology and conducts research related to growth factor receptors involved in vascular and smooth muscle biology.
- Thomson Reuters StreetEvents
Edited Transcript of LIFE earnings conference call or presentation 14-Aug-19 9:00pm GMT
Q2 2019 aTyr Pharma Inc Earnings Call
- GlobeNewswire
aTyr Pharma to Participate in September Conferences
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conferences in September. Management will be participating in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies, which is being held September 23-24 in New York. Management will also be presenting a company update at the Ladenburg Thalmann 2019 Healthcare Conference, which is being held Tuesday, September 24 in New York.
- GlobeNewswire
First Day of Dealings for UK Cannabis Investment Company
LONDON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- World High Life Plc (LIFE.TO), a CBD and medicinal cannabis investment vehicle, is pleased to announce that trading in its Ordinary Shares will commence at 8.00 a.m. today on the NEX Exchange Growth Market ("Admission"), under ticker LIFE and ISIN number GB00BK777P75. The Company will look to identify investment opportunities in the medicinal cannabis, hemp and CBD sectors globally with a particular interest in the UK and European markets. The Company’s investment strategy will focus on markets that are internationally recognised as having well-developed and reputable laws and regulations relating to the research and production of medicinal cannabis, hemp and CBD, as well as therapeutic Cannabis derivatives including but not limited to nutraceuticals, dietary supplements and cosmetic products. The Directors believe that there are numerous investment opportunities within the CBD wellness industry, the hemp industry and the medicinal cannabis industry.
- GlobeNewswire
aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company update at the H.C. Wainwright 21st Annual Global Investment Conference, which is being held September 8-10 in New York.
- GlobeNewswire
aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and.
- GlobeNewswire
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
SAN DIEGO, Aug. 07, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the appointment of David Briscoe, MB, ChB, Director of the Transplant Research Program and Fellowship Program and Professor of Pediatrics at Harvard Medical School as scientific advisor to the company. “We are pleased to have attracted Dr. Briscoe as an advisor to help guide the expansion and development of our earlier stage pipeline based on NRP2 biology,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.
- GlobeNewswire
aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call and webcast on pulmonary sarcoidosis and the current treatment landscape on Thursday, July 18th at 2pm Eastern Time/11am Pacific Time. The call will feature a presentation by KOL Daniel Culver, DO, from the Cleveland Clinic, who will discuss the current standard of care and unmet medical need in treating patients with pulmonary sarcoidosis.
- GlobeNewswire
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross, Ph.D. and Svetlana Lucas, Ph.D. to the Company’s Board of Directors. “As we continue to advance ATYR1923 through clinical development in pulmonary sarcoidosis and further expand our pipeline of therapeutic candidates, we believe their respective skill sets in research and development and business development are ideally suited to help guide us through our next phase of growth. Dr. Jane Gross is an accomplished executive with more than 28 years of experience leading research and development in the design and development of therapeutics for the treatment of autoimmune, inflammatory diseases and cancer. Dr. Gross has deep experience in research and development, partnering and alliance management of multiple internal and co-development programs.
- GlobeNewswire
aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock split of its common stock that is scheduled to become effective after trading closes on June 28, 2019. The company’s common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on July 1, 2019. The company’s common stock will continue to trade under the symbol “LIFE.” At the company’s Annual Meeting of Stockholders held on May 8, 2019, the company’s stockholders approved a proposal authorizing the company’s Board of Directors to effect a reverse stock split in a range of 1:3 to 1:15 to help regain compliance with the Nasdaq minimum bid price requirement.
- Thomson Reuters StreetEvents
Edited Transcript of LIFE earnings conference call or presentation 13-May-19 9:00pm GMT
Q1 2019 aTyr Pharma Inc Earnings Call
- Associated Press
Atyr Pharma: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 18 cents. In the final minutes of trading on Monday, the company's shares hit 53 cents. A year ago, they were trading at $2.30. _____ ...
- GlobeNewswire
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2.
- GlobeNewswire
aTyr Pharma to Announce First Quarter 2019 Results on May 13th
SAN DIEGO, May 06, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will host a summit meeting on Neuropilin-2 (NRP-2) biology on April 17, 2019 in San Diego. This one-day summit meeting will bring together key researchers from across the United States to discuss the most recent discoveries relating to the development of therapeutics directed to the NRP-2 co-receptor, and related signaling pathways. “We are pleased to host this inaugural summit meeting which should serve to advance our collective understanding of the emerging role of NRP-2 in modulating immune responses across a broad range of disease states,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.
- GlobeNewswire
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated Kaufmann Small Cap Fund and Paul Schimmel, Ph.D., an existing stockholder and a director of the company, to purchase an aggregate of $5.0 million of aTyr’s common stock in a registered direct offering conducted without an underwriter or placement agent. Proceeds from the offering will be used to advance clinical development of aTyr’s lead therapeutic candidate, ATYR1923, and for other general corporate purposes. The securities described above are being offered pursuant to a shelf registration statement (File No. 333-211998) filed with the Securities and Exchange Commission (SEC), which was declared effective on June 22, 2016.
- Thomson Reuters StreetEvents
Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT
Q4 2018 aTyr Pharma Inc Earnings Call
- GlobeNewswire
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will present an abstract in a poster presentation at the American Thoracic Society (ATS) 2019 International Conference, which is being held May 19-22 in Dallas. ”We are very pleased to present these compelling results at this year’s ATS conference, which highlight ATYR1923’s unique mechanism of action and demonstrate activity in a range of ILD models,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “Notably, ATYR1923 appears to show potent immunomodulatory effects in models of fibrosing ILD that are highly inflammatory or T cell driven.
- Zacks
Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Associated Press
Atyr Pharma: 4Q Earnings Snapshot
The San Diego-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $34.5 million, or $1.15 per share. In the final minutes of trading on ...
